Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
Thrombosis & Haemostasis Journal (TH Open) has recently shared a promising data on Emicizumab efficacy on X:
”Implementing an Assay to detect Anti-drug Antibody against Emicizumab: Experience from One Center in France. Auditeau et al. evaluated the effectiveness of a modified bridging ELISA in detecting anti-drug antibodies.”
Read the full article here.
A bispecific antibody mimicking factor VIII, is approved for prophylaxis in hemophilia A — but what could possibly go wrong with a drug designed to work perfectly?
Although rare, anti-drug antibodies (ADA) can reduce its efficacy,using data from One center in France.
The study by Claire Auditeau et al. aimed to investigate potential causes behind the loss of Emicizumab efficacy.
Using a modified bridging ELISA, ADA was detected in two patients—one newly identified with a neutralizing ADA that blocked Emicizumab’s binding to factors IX and X.
In ADA-negative cases, bispecific antibody’s levels improved following adherence adjustments.
The findings suggest that the assay may help distinguish ADA-related loss of efficacy from non-immunologic causes in patients with unexplained bleeding.
Updates on thrombosis and hemostasis field advancements featured in Hemostasis Today.
-
Jul 11, 2025, 19:14ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
-
Jul 11, 2025, 16:48GPAS 2025: Shaping the Future of Bleeding Disorder Care
-
Jul 10, 2025, 11:23HTRS Thanks CSL Behring for Its Ongoing Commitment to Research Support
-
Jul 9, 2025, 14:11Join Dr. Bethany Samuelson Bannow for a Virtual Event on Hemostasis and Cancer
-
Jul 9, 2025, 13:59Late-Breaking Insights from ISTH 2025: Rurioctocog Alfa Pegol in PUPs with Hemophilia A
-
Jul 11, 2025, 18:50ICAS Not a Factor: Post-EVT Intensive BP Control within 24 hrs Worsens Outcomes
-
Jul 11, 2025, 17:57Need for Recanalization Strategies Reinforced in P1 and P2: PCA Stroke Poor Outcomes
-
Jul 11, 2025, 15:40Wolfgang Miesbach: How to Better Understand and Explain Gene Therapy of Haemophilia?
-
Jul 11, 2025, 14:53Thrombosis with Thrombocytopenia, Post Vaccination Syndrome
-
Jul 10, 2025, 18:16Sex-Specific Models for ASAH Show No Added Benefit over SMA2SH2ERS risk predictions
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 6, 2025, 21:00From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems
-
Jul 6, 2025, 14:56Missed ISTH 2025? Congress Daily Has You Covered
-
Jul 6, 2025, 11:48Japan's Youth Engagement in Hemophilia Care: Where Even the Doctors Get It – HABIT Summit 2025